Nimulid Strong Partners with Patna Pirates for PKL Season 12
Mankind Pharma’s Nimulid Strong, featuring 2.32% diclofenac for double-strength pain relief, has become the Official Pain Relief Partner of Patna Pirates for Pro Kabaddi League Season 12.
Mankind Pharma’s Nimulid Strong, featuring 2.32% diclofenac for double-strength pain relief, has become the Official Pain Relief Partner of Patna Pirates for Pro Kabaddi League Season 12. Designed for quick action in just 2 minutes, the gel and spray formats target neck pain from intense kabaddi movements. The brand has sold 20 lakh gel and 10 lakh spray units in its first year.
After the announcement on August 27, 2025, Mankind Pharma’s flagship brand Nimulid Strong has officially partnered with the Patna Pirates as the Official Pain Relief Partner for Pro Kabaddi League Season 12. This collaboration aligns the brand’s powerful pain relief formula with the intense physical demands of kabaddi, a sport known for sudden pulls, rapid twists, and heavy tackles that strain the neck and body. Nimulid Strong stands out in the topical pain relief market, which is valued at over ₹5,000 crore in India, by offering a 2.32% diclofenac concentration, double the standard 1.16% found in most products.
Mr. Joy Chatterjee, Vice President of Sales and Marketing at Mankind Pharma, emphasized that the partnership celebrates India’s indigenous sport while supporting athletes and everyday warriors who push through pain. Nimulid Strong’s formula provides relief in just 2 minutes, making it ideal for players who need instant recovery.
The brand has seen remarkable market performance in its first year, selling around 20 lakh gel units and 10 lakh spray units. Nimulid Strong is available as a gel for deep-penetrating, long-lasting relief, and as a spray for on-the-go convenience. Mankind Pharma plans to expand the brand’s offerings with innovative formats like balms, roll-ons, and tablets, reinforcing its commitment to effective and accessible pain relief solutions.
0
0
0
0
0
0
Comments
Sign up or log in to your account to leave comments and reactions
0 Comments